SUMMIYA AZEEM-Kech ...

In late December, an increase in cases of human metapneumovirus (HMPV ... does not view it as a novel or alarming threat. In the United States, HMPV accounts for less than 2% of respiratory ...

Vir Biotechnology, Inc.’s VIR share price has dipped by 5.45%, which has investors questioning if this is right time to buy.

A Spanish study found that nirsevimab prophylaxis significantly reduced infant hospitalizations, ICU admissions, and severe ...

It said the United States’ withdrawal from the ... “The prevalence of Human Metapneumovirus (HMPV), while still below 1% in Malaysia, signals the need for more development of vaccines in ...

Human metapneumovirus, while uncommon (<4% of outbreaks ... Analyses were performed in SAS 9.4 (SAS Institute Inc., Cary, North Carolina, United States). For statistical significance, differences in ...

Moderna is conducting a phase 1 trial of mRNA-1365 as combination vaccine for RSV and human metapneumovirus ... which is the leading cause of infant hospitalization in the United States, is clear. But ...

Mr. Espérance, the director of a human rights organization, wrote from Port-au-Prince, Haiti. Almost every night, I get phone calls from people in areas of Port-au-Prince, Haiti, under attack by ...